Heart transplantation in adult congenital heart disease

Luke Burchill

    Research output: Contribution to journalArticle

    12 Citations (Scopus)

    Abstract

    Heart failure (HF) in adult congenital heart disease (ACHD) is vastly different to that observed in acquired heart disease. Unlike acquired HF in which pharmacological strategies are the cornerstone for protecting and improving ventricular function, ACHDrelated HF relies heavily upon structural and other interventions to achieve these aims. patients with ACHD constitute a small percentage of the total adult heart transplant population (∼3%), although the number of ACHD heart transplant recipients is growing rapidly with a 40% increase over the last two decades. The worldwide experience to date has confirmed heart transplantation as an effective life-extending treatment option in carefully selected patients with ACHD with end-stage cardiac disease. Opportunities for improving outcomes in patients with ACHD-related HF include (i) earlier recognition and referral to centres with combined expertise in ACHD and HF, (ii) increased awareness of arrhythmia and sudden cardiac death risk in this population, (iii) greater collaboration between HF and ACHD specialists at the time of heart transplant assessment, (iv) expert surgical planning to reduce ischaemic time and bleeding risk at the time of transplant, (v) tailored immunosuppression in the posttransplant period and (vi) development and validation of ACHD-specific risk scores to predict mortality and guide patient selection. The purpose of this article is to review current approaches to diagnosing and treating advanced HF in patients with ACHD including indications, contraindications and clinical outcomes after heart transplantation.

    Original languageEnglish (US)
    Pages (from-to)1871-1877
    Number of pages7
    JournalHeart
    Volume102
    Issue number23
    DOIs
    StatePublished - Dec 1 2016

    Fingerprint

    Heart Transplantation
    Heart Diseases
    Heart Failure
    Transplants
    Bleeding Time
    Ventricular Function
    Sudden Cardiac Death
    Immunosuppression
    Patient Selection
    Population
    Cardiac Arrhythmias
    Referral and Consultation
    Pharmacology
    Mortality

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine

    Cite this

    Heart transplantation in adult congenital heart disease. / Burchill, Luke.

    In: Heart, Vol. 102, No. 23, 01.12.2016, p. 1871-1877.

    Research output: Contribution to journalArticle

    Burchill, Luke. / Heart transplantation in adult congenital heart disease. In: Heart. 2016 ; Vol. 102, No. 23. pp. 1871-1877.
    @article{5fdf6e877f7c4f63a2c3365dd0470216,
    title = "Heart transplantation in adult congenital heart disease",
    abstract = "Heart failure (HF) in adult congenital heart disease (ACHD) is vastly different to that observed in acquired heart disease. Unlike acquired HF in which pharmacological strategies are the cornerstone for protecting and improving ventricular function, ACHDrelated HF relies heavily upon structural and other interventions to achieve these aims. patients with ACHD constitute a small percentage of the total adult heart transplant population (∼3{\%}), although the number of ACHD heart transplant recipients is growing rapidly with a 40{\%} increase over the last two decades. The worldwide experience to date has confirmed heart transplantation as an effective life-extending treatment option in carefully selected patients with ACHD with end-stage cardiac disease. Opportunities for improving outcomes in patients with ACHD-related HF include (i) earlier recognition and referral to centres with combined expertise in ACHD and HF, (ii) increased awareness of arrhythmia and sudden cardiac death risk in this population, (iii) greater collaboration between HF and ACHD specialists at the time of heart transplant assessment, (iv) expert surgical planning to reduce ischaemic time and bleeding risk at the time of transplant, (v) tailored immunosuppression in the posttransplant period and (vi) development and validation of ACHD-specific risk scores to predict mortality and guide patient selection. The purpose of this article is to review current approaches to diagnosing and treating advanced HF in patients with ACHD including indications, contraindications and clinical outcomes after heart transplantation.",
    author = "Luke Burchill",
    year = "2016",
    month = "12",
    day = "1",
    doi = "10.1136/heartjnl-2015-309074",
    language = "English (US)",
    volume = "102",
    pages = "1871--1877",
    journal = "Heart",
    issn = "1355-6037",
    publisher = "BMJ Publishing Group",
    number = "23",

    }

    TY - JOUR

    T1 - Heart transplantation in adult congenital heart disease

    AU - Burchill, Luke

    PY - 2016/12/1

    Y1 - 2016/12/1

    N2 - Heart failure (HF) in adult congenital heart disease (ACHD) is vastly different to that observed in acquired heart disease. Unlike acquired HF in which pharmacological strategies are the cornerstone for protecting and improving ventricular function, ACHDrelated HF relies heavily upon structural and other interventions to achieve these aims. patients with ACHD constitute a small percentage of the total adult heart transplant population (∼3%), although the number of ACHD heart transplant recipients is growing rapidly with a 40% increase over the last two decades. The worldwide experience to date has confirmed heart transplantation as an effective life-extending treatment option in carefully selected patients with ACHD with end-stage cardiac disease. Opportunities for improving outcomes in patients with ACHD-related HF include (i) earlier recognition and referral to centres with combined expertise in ACHD and HF, (ii) increased awareness of arrhythmia and sudden cardiac death risk in this population, (iii) greater collaboration between HF and ACHD specialists at the time of heart transplant assessment, (iv) expert surgical planning to reduce ischaemic time and bleeding risk at the time of transplant, (v) tailored immunosuppression in the posttransplant period and (vi) development and validation of ACHD-specific risk scores to predict mortality and guide patient selection. The purpose of this article is to review current approaches to diagnosing and treating advanced HF in patients with ACHD including indications, contraindications and clinical outcomes after heart transplantation.

    AB - Heart failure (HF) in adult congenital heart disease (ACHD) is vastly different to that observed in acquired heart disease. Unlike acquired HF in which pharmacological strategies are the cornerstone for protecting and improving ventricular function, ACHDrelated HF relies heavily upon structural and other interventions to achieve these aims. patients with ACHD constitute a small percentage of the total adult heart transplant population (∼3%), although the number of ACHD heart transplant recipients is growing rapidly with a 40% increase over the last two decades. The worldwide experience to date has confirmed heart transplantation as an effective life-extending treatment option in carefully selected patients with ACHD with end-stage cardiac disease. Opportunities for improving outcomes in patients with ACHD-related HF include (i) earlier recognition and referral to centres with combined expertise in ACHD and HF, (ii) increased awareness of arrhythmia and sudden cardiac death risk in this population, (iii) greater collaboration between HF and ACHD specialists at the time of heart transplant assessment, (iv) expert surgical planning to reduce ischaemic time and bleeding risk at the time of transplant, (v) tailored immunosuppression in the posttransplant period and (vi) development and validation of ACHD-specific risk scores to predict mortality and guide patient selection. The purpose of this article is to review current approaches to diagnosing and treating advanced HF in patients with ACHD including indications, contraindications and clinical outcomes after heart transplantation.

    UR - http://www.scopus.com/inward/record.url?scp=84991826520&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84991826520&partnerID=8YFLogxK

    U2 - 10.1136/heartjnl-2015-309074

    DO - 10.1136/heartjnl-2015-309074

    M3 - Article

    C2 - 27836946

    AN - SCOPUS:84991826520

    VL - 102

    SP - 1871

    EP - 1877

    JO - Heart

    JF - Heart

    SN - 1355-6037

    IS - 23

    ER -